268 related articles for article (PubMed ID: 29415856)
1. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
Marcus R; Bojko MJ; Mazhnaya A; Makarenko I; Filippovych S; Dvoriak S; Altice FL; Springer SA
J Subst Abuse Treat; 2018 Mar; 86():86-93. PubMed ID: 29415856
[TBL] [Abstract][Full Text] [Related]
2. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.
Marcus R; Makarenko I; Mazhnaya A; Zelenev A; Polonsky M; Madden L; Filippovych S; Dvoriak S; Springer SA; Altice FL
Drug Alcohol Depend; 2017 Oct; 179():213-219. PubMed ID: 28806638
[TBL] [Abstract][Full Text] [Related]
3. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
[TBL] [Abstract][Full Text] [Related]
4. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.
Makarenko I; Pykalo I; Springer SA; Mazhnaya A; Marcus R; Filippovich S; Dvoriak S; Altice FL
J Subst Abuse Treat; 2019 Sep; 104():34-41. PubMed ID: 31370983
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
6. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
7. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
Hoffman KA; Baker R; Fanucchi LC; Lum PJ; Kunkel LE; Ponce Terashima J; McCarty D; Jacobs P; Korthuis PT
Addict Sci Clin Pract; 2021 Nov; 16(1):67. PubMed ID: 34758887
[TBL] [Abstract][Full Text] [Related]
9. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
10. Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans.
Rigg KK
Drug Alcohol Depend; 2024 Apr; 257():111260. PubMed ID: 38492256
[TBL] [Abstract][Full Text] [Related]
11. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
[TBL] [Abstract][Full Text] [Related]
12. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
14. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Korthuis PT; Cook RR; Lum PJ; Waddell EN; Tookes H; Vergara-Rodriguez P; Kunkel LE; Lucas GM; Rodriguez AE; Bielavitz S; Fanucchi LC; Hoffman KA; Bachrach K; Payne EH; Collins JA; Matthews A; Oden N; Jacobs P; Jelstrom E; Sorensen JL; McCarty D
Addiction; 2022 Jul; 117(7):1961-1971. PubMed ID: 35129242
[TBL] [Abstract][Full Text] [Related]
15. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
16. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with willingness to take extended release naltrexone among injection drug users.
Ahamad K; Milloy MJ; Nguyen P; Uhlmann S; Johnson C; Korthuis TP; Kerr T; Wood E
Addict Sci Clin Pract; 2015 May; 10():12. PubMed ID: 25935714
[TBL] [Abstract][Full Text] [Related]
19. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
20. Extended-release naltrexone for opioid use disorder started during or following incarceration.
Lincoln T; Johnson BD; McCarthy P; Alexander E
J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
